Suppr超能文献

共聚体1除了阻断主要组织相容性复合体外,还通过T细胞受体拮抗作用对抗髓鞘碱性蛋白的免疫显性表位82 - 100。

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.

作者信息

Aharoni R, Teitelbaum D, Arnon R, Sela M

机构信息

Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel.

出版信息

Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):634-9. doi: 10.1073/pnas.96.2.634.

Abstract

The synthetic random amino acid copolymer Copolymer 1 (Cop 1, Copaxone, glatiramer acetate) suppresses experimental autoimmune encephalomyelitis, slows the progression of disability, and reduces relapse rate in multiple sclerosis (MS). Cop 1 binds to various class II major histocompatibility complex (MHC) molecules and inhibits the T cell responses to several myelin antigens. In this study we attempted to find out whether, in addition to MHC blocking, Cop 1, which is immunologically cross-reactive with myelin basic protein (MBP), inhibits the response to this autoantigen by T cell receptor (TCR) antagonism. Two experimental systems, "prepulse assay" and "split APC assay," were used to discriminate between competition for MHC molecules and TCR antagonism. The results in both systems using T cell lines/clones from mouse and human origin indicated that Cop 1 is a TCR antagonist of the 82-100 epitope of MBP. In contrast to the broad specificity of the MHC blocking induced by Cop 1, its TCR antagonistic activity was restricted to the 82-100 determinant of MBP and could not be demonstrated for proteolipid protein peptide or even for other MBP epitopes. Yet, it was shown for all the MBP 82-100-specific T cell lines/clones tested that were derived from mice as well as from an MS patient. The ability of Cop 1 to act as altered peptide and induce TCR antagonistic effect on the MBP p82-100 immunodominant determinant response elucidates further the mechanism of Cop 1 therapeutic activity in experimental autoimmune encephalomyelitis and MS.

摘要

合成随机氨基酸共聚物共聚物1(Cop 1,考帕松,醋酸格拉替雷)可抑制实验性自身免疫性脑脊髓炎,减缓残疾进展,并降低多发性硬化症(MS)的复发率。Cop 1与多种II类主要组织相容性复合体(MHC)分子结合,并抑制T细胞对多种髓鞘抗原的反应。在本研究中,我们试图弄清楚,除了MHC阻断作用外,与髓鞘碱性蛋白(MBP)具有免疫交叉反应性的Cop 1是否通过T细胞受体(TCR)拮抗作用来抑制对这种自身抗原的反应。使用了“预脉冲测定法”和“分离抗原呈递细胞测定法”这两种实验系统来区分对MHC分子的竞争和TCR拮抗作用。使用源自小鼠和人类的T细胞系/克隆进行的这两种系统的结果表明,Cop 1是MBP 82 - 100表位的TCR拮抗剂。与Cop 1诱导的MHC阻断的广泛特异性不同,其TCR拮抗活性仅限于MBP的82 - 100决定簇,对于蛋白脂蛋白肽甚至其他MBP表位都无法证明有这种活性。然而,对于所有测试的源自小鼠以及一名MS患者的MBP 82 - 100特异性T细胞系/克隆都证明了这一点。Cop 1作为改变肽并对MBP p82 - 100免疫显性决定簇反应诱导TCR拮抗作用的能力,进一步阐明了Cop 1在实验性自身免疫性脑脊髓炎和MS中的治疗活性机制。

相似文献

引用本文的文献

5
Multiple Sclerosis: Therapeutic Strategies on the Horizon.多发性硬化症:即将出现的治疗策略。
Cureus. 2022 May 10;14(5):e24895. doi: 10.7759/cureus.24895. eCollection 2022 May.
8
Immunological Aspects of Approved MS Therapeutics.已获批多发性硬化症治疗药物的免疫学方面。
Front Immunol. 2019 Jul 11;10:1564. doi: 10.3389/fimmu.2019.01564. eCollection 2019.
10
The Evolving Mechanisms of Action of Glatiramer Acetate.醋酸格拉替雷作用机制的演变。
Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):a029249. doi: 10.1101/cshperspect.a029249.

本文引用的文献

1
Major T-cell responses in multiple sclerosis.多发性硬化症中的主要T细胞反应。
Mol Med Today. 1995 May;1(2):79-83. doi: 10.1016/s1357-4310(95)92366-7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验